The Breast Tissue Markers Market was valued at USD 775.8 million in 2024, and is projected to reach USD 1.16 billion by 2030, rising at a CAGR of 7.00%. The key factors driving market growth include the increasing incidence of breast cancer, increasing awareness regarding early detection, and growing adoption of minimally invasive diagnostic procedures. Supportive government initiatives and screening programs, along with a growing geriatric population prone to cancer, further propel market growth. According to the World Band data, around 19% of the total female population in the U.S. was aged 65 years and above in 2023, a significant rise over the past years.
The increasing incidence of breast cancer globally and the rising adoption of minimally invasive procedures are some of the major factors driving market growth. For instance, according to the American Cancer Society, breast cancer is the most common type of cancer in women in the U.S., accounting for around 30% of all cancer cases. Moreover, it is estimated that in 2025, around 316,950 new invasive breast cancer cases can be diagnosed, and around 59,080 new cases of ductal carcinoma in situ (DCIS) can be diagnosed, while breast cancer is expected to cause around 42,170 mortalities in the same year. This high prevalence of breast cancer has significantly increased the focus on early detection through mammography and image-guided biopsies, thereby increasing the demand for accurate localization and tracking solutions.
Technological advancements in the design and composition of breast tissue markers have significantly contributed to market growth. Traditional metallic clips have evolved into bio-compatible markers with distinct shapes and radiopacity profiles that improve visibility across various imaging platforms. Manufacturers are investing in developing 3D-shaped markers, polymer-embedded markers, and bio-absorbable designs that minimize migration, reduce artifacts in post-placement imaging, and offer improved compatibility with MRI and mammography.
For instance, in March 2024, Mammotome announced the 510(k) clearance of its LumiMARK Biopsy Site Marker, a novel tissue marker designed for enhanced visibility across ultrasound, mammography, and MRI. Developed in collaboration with radiologists, the self-expanding nitinol markers come in three distinct 3D shapes-Tulip, Lotus, and Rose-to support various clinical scenarios. 510(k) are cleared for marking breast tissue and axillary lymph nodes. Its design aims to improve accuracy in biopsy site localization and patient care during follow-up procedures. These innovations improve the workflow and reduce patient discomfort and complications, increasing the demand for these breast tissue markers in healthcare facilities.
Moreover, the market growth is also driven by increased initiatives and funding from government bodies and organizations dedicated to cancer prevention and early detection. For instance, in January 2025, the CDC announced a five-year, USD 2.3 million fund to Weill Cornell Medicine to enhance care for young breast cancer patients, focusing on diverse populations in New York City. Led by Drs. Vered Stearns and Tessa Cigler, the initiative aims to improve access, education, and support services, addressing physical and cultural needs to boost treatment adherence and survival outcomes.
Similarly, various programs such as the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) further increase women's access to breast cancer screenings. For instance, since its inception, the NBCCEDP has facilitated over 16.5 million breast and cervical cancer screenings, diagnosing nearly 80,000 invasive breast cancers. The convergence of governmental support, funding, and public health campaigns is expected to contribute to market growth over the forecast period.
This product will be delivered within 2 business days.
The increasing incidence of breast cancer globally and the rising adoption of minimally invasive procedures are some of the major factors driving market growth. For instance, according to the American Cancer Society, breast cancer is the most common type of cancer in women in the U.S., accounting for around 30% of all cancer cases. Moreover, it is estimated that in 2025, around 316,950 new invasive breast cancer cases can be diagnosed, and around 59,080 new cases of ductal carcinoma in situ (DCIS) can be diagnosed, while breast cancer is expected to cause around 42,170 mortalities in the same year. This high prevalence of breast cancer has significantly increased the focus on early detection through mammography and image-guided biopsies, thereby increasing the demand for accurate localization and tracking solutions.
Technological advancements in the design and composition of breast tissue markers have significantly contributed to market growth. Traditional metallic clips have evolved into bio-compatible markers with distinct shapes and radiopacity profiles that improve visibility across various imaging platforms. Manufacturers are investing in developing 3D-shaped markers, polymer-embedded markers, and bio-absorbable designs that minimize migration, reduce artifacts in post-placement imaging, and offer improved compatibility with MRI and mammography.
For instance, in March 2024, Mammotome announced the 510(k) clearance of its LumiMARK Biopsy Site Marker, a novel tissue marker designed for enhanced visibility across ultrasound, mammography, and MRI. Developed in collaboration with radiologists, the self-expanding nitinol markers come in three distinct 3D shapes-Tulip, Lotus, and Rose-to support various clinical scenarios. 510(k) are cleared for marking breast tissue and axillary lymph nodes. Its design aims to improve accuracy in biopsy site localization and patient care during follow-up procedures. These innovations improve the workflow and reduce patient discomfort and complications, increasing the demand for these breast tissue markers in healthcare facilities.
Moreover, the market growth is also driven by increased initiatives and funding from government bodies and organizations dedicated to cancer prevention and early detection. For instance, in January 2025, the CDC announced a five-year, USD 2.3 million fund to Weill Cornell Medicine to enhance care for young breast cancer patients, focusing on diverse populations in New York City. Led by Drs. Vered Stearns and Tessa Cigler, the initiative aims to improve access, education, and support services, addressing physical and cultural needs to boost treatment adherence and survival outcomes.
Similarly, various programs such as the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) further increase women's access to breast cancer screenings. For instance, since its inception, the NBCCEDP has facilitated over 16.5 million breast and cervical cancer screenings, diagnosing nearly 80,000 invasive breast cancers. The convergence of governmental support, funding, and public health campaigns is expected to contribute to market growth over the forecast period.
Global Breast Tissue Markers Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global breast tissue markers market report based on product, material, usage type, end use, and region:Product Outlook (Revenue, USD Million, 2018-2030)
- Coil
- Ribbon
- Wing
- U Shaped
- Conic
- Ring
- Heart
- Venus
- Others
Material Outlook (Revenue, USD Million, 2018-2030)
- Bio-absorbable
- Non-absorbable
Usage Type Outlook (Revenue, USD Million, 2018-2030)
- Biopsy
- Stereotactic
- Ultrasound
- MRI-guided
- Surgical Planning
- Others
End Use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Diagnostic Centers
- Specialty Clinics
Regional Outlook (Revenue, USD Million, 2018-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- Italy
- France
- Spain
- Denmark
- Sweden
- Norway
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Breast Tissue Markers Market Variables, Trends, & Scope
Chapter 4. Breast Tissue Markers Market: Product Estimates & Trend Analysis
Chapter 5. Breast Tissue Markers Market: Material Estimates & Trend Analysis
Chapter 6. Breast Tissue Markers Market: Usage Type Estimates & Trend Analysis
Chapter 7. Breast Tissue Markers Market: End Use Estimates & Trend Analysis
Chapter 8. Breast Tissue Markers Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Breast Tissue Markers market report include:- BD
- Hologic
- INRAD, Inc.
- Carbon Medical Technologies, Inc.
- Vigeo srl
- MOLLI Surgical (Stryker)
- Mammotome
- Mermaid Medical
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 140 |
Published | May 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 775.8 Million |
Forecasted Market Value ( USD | $ 1160 Million |
Compound Annual Growth Rate | 7.0% |
Regions Covered | Global |
No. of Companies Mentioned | 9 |